100%
Skip to main content
Platform
GovTribe AI
AI-powered insights to accelerate your government contracting workflow.
MCP Server
Connect GovTribe to your AI tools.
Beacon
Find and connect with key government decision-makers.
Profiles
Federal Agencies
Federal Contract Vehicles
Federal Grant Programs
Major Defense Acquisition Programs
NAICS Categories
PSC Categories
States
Jurisdictions
NIGP Categories
UNSPSC Categories
Vendors
Enrichment By Clearbit
Reports
New Entrants
Funding Analysis
Vehicle Analysis
Groups
Capture
Pipelines
Pursuits
Alerts
Teaming
Data
Awards
Forecasts
Federal Opportunities
State & Local Opportunities
Files
Prime and Subcontractors
Activity
Search
Exports
Solutions
Use Case
Opportunity Identification
Capture Management
Competitive Intelligence
Teaming & Partner Identification
Proposal Management
Strategic Leadership
Go-to-Market Strategy
Industry
Federal Contractors
State & Local Contractors
Grant Seekers
Government Agencies
Research & Consulting
Pricing
More
About Us
Features
Get A Demo
Sign Up
Blog
User Guide
Data Model
GovTribe for Agents
Login
Contact sales
Try for free
Login
Contact sales
Try for free
All Federal Grant Awards
Project Grant R43CA246896
Award Date
7/1/20
Completion Date
3/31/22
Dollars Obligated
$225K
Overview
Activity
3
Transactions
3
Subawards
Similar Awards
Federal Agency
National Cancer Institute
Awardee
AVM Biotechnology, Inc. (D29NFMS3DJJ8)
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Washington, USA
Update #1
Update #2
A NOVEL NON-TOXIC PRECONDITIONING REGIMEN FOR CANCER CELL THERAPY
Posted 5/29/20
5
1
Mod #
Description
ReasonForModification
Federal Obligation
Date
Not listed
A NOVEL NON-TOXIC PRECONDITIONING REGIMEN FOR CANCER CELL THERAPY - PROJECT SUMMARY CELLULAR IMMUNOTHERAPY HAS THE POTENTIAL TO BECOME THE DEFINITIVE SOLUTION FOR CANCER. HOWEVER, TOXIC CHEMOTHERAPY IS CURRENTLY REQUIRED AS PRECONDITIONING TREATMENT TO IMPAIR GRAFT REJECTION AND MAINTAIN THERAPEUTIC CELLS IN THE BLOODSTREAM WHERE THEY CAN TARGET CANCER CELLS. CHEMOTHERAPY IS HARDLY TOLERATED BY FRAIL CANCER PATIENTS, AND IT FUELS THE SIDE EFFECTS OF IMMUNOTHERAPY SUCH AS TOXIC CYTOKINE RELEASES (CRS) AND NEUROEDEMAS. AVM BIOTECHNOLOGY (AVM) IS WORKING TOWARDS A NOVEL SAFE PRE-CONDITIONING REGIMEN, NAMED AVM0703, WHICH COULD BE EASILY ADMINISTERED TO INCREASE EFFICIENT DELIVERY OF ADOPTIVE CELLULAR IMMUNOTHERAPY. AVM0703 INDUCES SAFE LYMPHODEPLETION IN ONLY 24 HOURS, SPARING PLATELETS, STEM CELLS AND RED BLOOD CELLS. INTERESTINGLY, AVM0703 CAN SAFELY DEPLETE MONOCYTES, KNOWN TO BE A KEY INDUCER OF CRS. CRS TOXICITIES OCCUR AS FREQUENTLY AS 90% WITH HALF OF THEM DETERMINED AS SEVERE. SEVERE CRS COMPLICATIONS CAN BE LIFE THREATENING IF NOT TREATED IN A TIMELY MANNER. LEVELS OF IL-6 ARE ELEVATED DURING CRS AND ANIMAL STUDIES HAVE DEMONSTRATED THAT MONOCYTES ARE THE PRIMARY SOURCE OF IL-6. DEPLETION OF IL-6 PRODUCING MONOCYTES PROTECTED MICE FROM CRS-INDUCED LETHALITY. UNLIKE CHEMOTHERAPY, AVM0703 CAN SAFELY DEPLETE MONOCYTES REDUCING THE RISK OF CRS AND MAKING CELLULAR IMMUNOTHERAPY ACCESSIBLE TO HIGH-RISK INDIVIDUALS LIKE OLDER/FRAIL PATIENTS. AVM0703 MODE OF ACTION COULD OFFER AN EXEMPLARY PRECONDITIONING REGIMEN. TO ESTABLISH FEASIBILITY FOR THIS PRODUCT, WE PROPOSE THE FOLLOWING TWO SPECIFIC AIMS. AIM 1. EVALUATE THE EFFICACY OF AVM0703 AS PRECONDITIONING FOR T-CELL TRANSFUSION IN AN IMMUNOCOMPETENT MULTIPLE MYELOMA (MM) MOUSE MODEL. THE LEVEL OF LYMPHODEPLETION, IMPROVEMENT IN T CELL CIRCULATION, AND THE LEVEL OF CYTOTOXICITY INDUCED BY AVM0703 WILL BE MONITORED AND COMPARED TO STANDARD CHEMOTHERAPY. FINALLY, THE ABILITY TO GUARANTEE THE THERAPEUTIC EFFECT OF ALLOGENEIC T-CELLS WILL BE VALIDATED. AIM2. DEMONSTRATE IMPROVED SAFETY OF AVM0703 AND ITS ABILITY TO DECREASE RISKS OF CRS ASSOCIATED WITH THE INJECTION OF IMMUNOTHERAPEUTIC CELLS. THE SUCCESSFUL OUTCOME OF THIS PROJECT WILL PROVIDE THE SOLID CLINICAL FOUNDATION FOR THE USE OF AVM0703 AS PRECONDITIONING DRUG WITH CURRENT AND FUTURE ADOPTIVE CELLULAR THERAPIES, TO REMOVE THE NEED FOR CHEMOTHERAPY. DURING AN SBIR PHASE II PROJECT, AVM WILL COLLABORATE WITH CANCER CENTERS OF EXCELLENCE FOR THE GENERATION OF NOVEL CANCER CELL THERAPIES BASED ON THE USE OF AVM0703 TO DEMONSTRATE THEIR POTENTIAL IMPROVED CLINICAL OUTCOMES. ULTIMATELY, THE TOLERABLE REGIMEN OFFERED BY AVM0703 MIGHT DISRUPT THE FUTURE "CANCER CONCEPT" BECOMING A SIMPLE CHRONIC DISEASE TREATED WITH REPEATED ADMINISTRATIONS OF NON-TOXIC THERAPIES.
$0
11/9/22
Not listed
A NOVEL NON-TOXIC PRECONDITIONING REGIMEN FOR CANCER CELL THERAPY - PROJECT SUMMARY CELLULAR IMMUNOTHERAPY HAS THE POTENTIAL TO BECOME THE DEFINITIVE SOLUTION FOR CANCER. HOWEVER, TOXIC CHEMOTHERAPY IS CURRENTLY REQUIRED AS PRECONDITIONING TREATMENT TO IMPAIR GRAFT REJECTION AND MAINTAIN THERAPEUTIC CELLS IN THE BLOODSTREAM WHERE THEY CAN TARGET CANCER CELLS. CHEMOTHERAPY IS HARDLY TOLERATED BY FRAIL CANCER PATIENTS, AND IT FUELS THE SIDE EFFECTS OF IMMUNOTHERAPY SUCH AS TOXIC CYTOKINE RELEASES (CRS) AND NEUROEDEMAS. AVM BIOTECHNOLOGY (AVM) IS WORKING TOWARDS A NOVEL SAFE PRE-CONDITIONING REGIMEN, NAMED AVM0703, WHICH COULD BE EASILY ADMINISTERED TO INCREASE EFFICIENT DELIVERY OF ADOPTIVE CELLULAR IMMUNOTHERAPY. AVM0703 INDUCES SAFE LYMPHODEPLETION IN ONLY 24 HOURS, SPARING PLATELETS, STEM CELLS AND RED BLOOD CELLS. INTERESTINGLY, AVM0703 CAN SAFELY DEPLETE MONOCYTES, KNOWN TO BE A KEY INDUCER OF CRS. CRS TOXICITIES OCCUR AS FREQUENTLY AS 90% WITH HALF OF THEM DETERMINED AS SEVERE. SEVERE CRS COMPLICATIONS CAN BE LIFE THREATENING IF NOT TREATED IN A TIMELY MANNER. LEVELS OF IL-6 ARE ELEVATED DURING CRS AND ANIMAL STUDIES HAVE DEMONSTRATED THAT MONOCYTES ARE THE PRIMARY SOURCE OF IL-6. DEPLETION OF IL-6 PRODUCING MONOCYTES PROTECTED MICE FROM CRS-INDUCED LETHALITY. UNLIKE CHEMOTHERAPY, AVM0703 CAN SAFELY DEPLETE MONOCYTES REDUCING THE RISK OF CRS AND MAKING CELLULAR IMMUNOTHERAPY ACCESSIBLE TO HIGH-RISK INDIVIDUALS LIKE OLDER/FRAIL PATIENTS. AVM0703 MODE OF ACTION COULD OFFER AN EXEMPLARY PRECONDITIONING REGIMEN. TO ESTABLISH FEASIBILITY FOR THIS PRODUCT, WE PROPOSE THE FOLLOWING TWO SPECIFIC AIMS. AIM 1. EVALUATE THE EFFICACY OF AVM0703 AS PRECONDITIONING FOR T-CELL TRANSFUSION IN AN IMMUNOCOMPETENT MULTIPLE MYELOMA (MM) MOUSE MODEL. THE LEVEL OF LYMPHODEPLETION, IMPROVEMENT IN T CELL CIRCULATION, AND THE LEVEL OF CYTOTOXICITY INDUCED BY AVM0703 WILL BE MONITORED AND COMPARED TO STANDARD CHEMOTHERAPY. FINALLY, THE ABILITY TO GUARANTEE THE THERAPEUTIC EFFECT OF ALLOGENEIC T-CELLS WILL BE VALIDATED. AIM2. DEMONSTRATE IMPROVED SAFETY OF AVM0703 AND ITS ABILITY TO DECREASE RISKS OF CRS ASSOCIATED WITH THE INJECTION OF IMMUNOTHERAPEUTIC CELLS. THE SUCCESSFUL OUTCOME OF THIS PROJECT WILL PROVIDE THE SOLID CLINICAL FOUNDATION FOR THE USE OF AVM0703 AS PRECONDITIONING DRUG WITH CURRENT AND FUTURE ADOPTIVE CELLULAR THERAPIES, TO REMOVE THE NEED FOR CHEMOTHERAPY. DURING AN SBIR PHASE II PROJECT, AVM WILL COLLABORATE WITH CANCER CENTERS OF EXCELLENCE FOR THE GENERATION OF NOVEL CANCER CELL THERAPIES BASED ON THE USE OF AVM0703 TO DEMONSTRATE THEIR POTENTIAL IMPROVED CLINICAL OUTCOMES. ULTIMATELY, THE TOLERABLE REGIMEN OFFERED BY AVM0703 MIGHT DISRUPT THE FUTURE "CANCER CONCEPT" BECOMING A SIMPLE CHRONIC DISEASE TREATED WITH REPEATED ADMINISTRATIONS OF NON-TOXIC THERAPIES.
$0
11/9/22
Not listed
A NOVEL NON-TOXIC PRECONDITIONING REGIMEN FOR CANCER CELL THERAPY
$224.8k
5/29/20